OTLK (Outlook Therapeutics) Cyclically Adjusted PB Ratio: (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OTLK Outlook Therapeutics Inc OTLK
14 GF Score
Price $0.90
! 5 Warning Signs
View Full Analysis

What is Outlook Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Outlook Therapeutics  (NAS:OTLK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Outlook Therapeutics Cyclically Adjusted PB Ratio Related Terms


Outlook Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Cyclically Adjusted PB Ratio Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OTLK vs SLGL, SABS, LCTX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Cyclically Adjusted PB Ratio falls into.


OTLK
14GF Score
Outlook Therapeutics Inc OTLK
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Outlook Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Outlook Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.277/330.2130*330.2130
=-0.277

Current CPI (Mar. 2026) = 330.2130.

Outlook Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 10.930 241.018 14.975
201609 -36.175 241.428 -49.478
201612 -148.517 241.432 -203.131
201703 -177.841 243.801 -240.874
201706 -187.935 244.955 -253.347
201709 -215.712 246.819 -288.596
201712 -173.438 246.524 -232.316
201803 -225.012 249.554 -297.739
201806 -29.268 251.989 -38.354
201809 -56.641 252.439 -74.092
201812 -49.538 251.233 -65.111
201903 -47.765 254.202 -62.048
201906 -4.642 256.143 -5.984
201909 -11.279 256.759 -14.506
201912 -16.094 256.974 -20.681
202003 -4.573 258.115 -5.850
202006 1.736 257.797 2.224
202009 0.444 260.280 0.563
202012 -1.647 260.474 -2.088
202103 2.379 264.877 2.966
202106 1.459 271.696 1.773
202109 0.522 274.310 0.628
202112 4.354 278.802 5.157
202203 3.185 287.504 3.658
202206 1.778 296.311 1.981
202209 0.769 296.808 0.856
202212 1.228 296.797 1.366
202303 0.817 301.836 0.894
202306 -0.425 305.109 -0.460
202309 -1.110 307.789 -1.191
202312 -1.871 306.746 -2.014
202403 -6.098 312.332 -6.447
202406 -3.575 314.175 -3.757
202409 -3.057 315.301 -3.202
202412 -2.019 315.605 -2.112
202503 -0.987 319.799 -1.019
202506 -0.855 322.561 -0.875
202509 -0.597 324.800 -0.607
202512 -0.597 324.054 -0.608
202603 -0.277 330.213 -0.277

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
14GF Score

Get the complete analysis for OTLK

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.90
Price